Scandion Oncology (Scandion) today announces its Q4 & year-end report 2022. The following is taken from the report. Francois Martelet, CEO: “I am passionate about unlocking the potential of Scandion in drug resistance to the benefit of our many stakeholders, and – above all – the patients” Key Figures & Highlights TDKK Q4 2022 Q1-Q4 2022 Q4 2021 Q1-Q4 2021           Operating loss -15,387 -80,166 -14,553 -55,367           Net finance income/cost -300 -2,034 -261 -1,846           Loss before tax -15,687 -82,200 -14,814 -57,213           Net loss -76,700 -14,806 -51,705 -15,687           Total assets 89,401 89,401 116,219 116,219           Cash Position 77,605 77,605 105,710 105,710           Total equity 70,327 70,327 104,541 104,541           Equity ratio 79% 79% 90% 90%           Earnings per share (EPS) -0.37 -1.87 -0.46 -1.61           Shares outstanding, ending 40,706,972 40,706,972 32,135,544 32,135,544           Highlights during Q4 2022 On October 10, Scandion initiates recruitment in part 3 of the CORIST phase II trial. The first of up to 36 patients has been enrolled in part 3 of the CORIST trial in accordance with the planned timeline On October 28, Scandion announce results of extraordinary general meeting, including adoption of authorization to issue shares both with and without pre-emptive rights for the Company’s existing shareholders, along with election of new board member, Nils Brünner On December 1, Scandion appoints Francois Martelet, M.D., as new Chief Executive Officer. Francois brings a wealth of highly relevant experiences to Scandion as an experienced and passionate business leader with the qualifications to successfully develop Scandion Highlights after the end of the period On January 18, Scandion appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management. Jan is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research On January 19, Scandion receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101. The patent would provide protection of the commercial solid form of SCO-101 until at least 2042 The Q4 & year-end report 2022 is available on the Company’s website: www.scandiononcology.com. Audiocast today, February 22 at 10:00 am CET Today at 10:00, Scandion Oncology’s executive management […]

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will publish its 2022 Q4 & year-end report on Wednesday February 22, 2023, before 09:00 CET. Scandion’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event can be obtained as follows: LIVE access on Wednesday February 22, 2023, at 10:00 CET Webcast: https://financialhearings.com/event/46153 REPLAY accessWebcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com For further information please contact:Johnny Stilou, CFOPhone: +45 2960 3532E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on February 15, 2023, at 17.30 CET. Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer. Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are related to cancer drug resistance. Our medicines could be relevant in several cancers and makes both our medical and commercial potential significant. Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250. AttachmentsInvitation To Scandion Oncology Webcast And Conference Call Year End 2022 Invitation To Scandion Oncology Webcast And Conference Call Year End 2022